MX2022008614A - Esteroides neuroactivos y composicion farmaceutica que contiene los mismos. - Google Patents

Esteroides neuroactivos y composicion farmaceutica que contiene los mismos.

Info

Publication number
MX2022008614A
MX2022008614A MX2022008614A MX2022008614A MX2022008614A MX 2022008614 A MX2022008614 A MX 2022008614A MX 2022008614 A MX2022008614 A MX 2022008614A MX 2022008614 A MX2022008614 A MX 2022008614A MX 2022008614 A MX2022008614 A MX 2022008614A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
containing same
neuroactive steroids
nas
Prior art date
Application number
MX2022008614A
Other languages
English (en)
Spanish (es)
Inventor
Lianhong Xu
Guiling Zhao
Original Assignee
Brii Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brii Biosciences Inc filed Critical Brii Biosciences Inc
Publication of MX2022008614A publication Critical patent/MX2022008614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022008614A 2020-01-12 2021-01-12 Esteroides neuroactivos y composicion farmaceutica que contiene los mismos. MX2022008614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959977P 2020-01-12 2020-01-12
PCT/US2021/013112 WO2021142477A1 (en) 2020-01-12 2021-01-12 Neuroactive steroids and pharmaceutical composition containing the same

Publications (1)

Publication Number Publication Date
MX2022008614A true MX2022008614A (es) 2022-10-10

Family

ID=76788885

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008614A MX2022008614A (es) 2020-01-12 2021-01-12 Esteroides neuroactivos y composicion farmaceutica que contiene los mismos.

Country Status (11)

Country Link
US (1) US20230118577A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087854A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023509798A (cg-RX-API-DMAC7.html)
KR (1) KR20230031812A (cg-RX-API-DMAC7.html)
CN (1) CN115244065B (cg-RX-API-DMAC7.html)
AU (1) AU2021206712A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013585A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167331A1 (cg-RX-API-DMAC7.html)
IL (1) IL294606A (cg-RX-API-DMAC7.html)
MX (1) MX2022008614A (cg-RX-API-DMAC7.html)
WO (1) WO2021142477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020231837A1 (en) 2019-05-10 2020-11-19 Brii Biosciences, Inc. Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
JP7670626B2 (ja) * 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1359646A (fr) * 1962-11-22 1964-04-30 Roussel Uclaf Procédé de préparation de dérivés stéroïdes et produits obtenus par ce procédé
NL6808141A (cg-RX-API-DMAC7.html) * 1967-06-16 1968-12-17
GB1409239A (en) * 1971-11-11 1975-10-08 Glaxo Lab Ltd Process for the preparation of 3alpha-hydroxy-5alpha-steroids
PH12018501923B1 (en) * 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
JP7670626B2 (ja) * 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
WO2021174205A1 (en) * 2020-02-27 2021-09-02 Brii Biosciences, Inc. Prodrugs of neuroactive steroids

Also Published As

Publication number Publication date
WO2021142477A1 (en) 2021-07-15
JP2023509798A (ja) 2023-03-09
EP4087854A1 (en) 2022-11-16
EP4087854A4 (en) 2024-02-28
CA3167331A1 (en) 2021-07-15
US20230118577A1 (en) 2023-04-20
CN115244065A (zh) 2022-10-25
KR20230031812A (ko) 2023-03-07
IL294606A (en) 2022-09-01
CN115244065B (zh) 2025-09-09
AU2021206712A1 (en) 2022-07-28
BR112022013585A2 (pt) 2022-09-13

Similar Documents

Publication Publication Date Title
CL2020002032A1 (es) Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325).
CO2021013140A2 (es) Derivado de pirazina y aplicación del mismo en la inhibición de shp2
MX2024001108A (es) Composiciones y metodos para la inhibicion del gen de virus de sarcoma de rata (ras).
BR112022013585A2 (pt) Esteroides neuroativos e composição farmacêutica que contém os mesmos
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
PY21109835A (es) Compuestos novedosos, métodos para su fabricación, y usos de los mismos
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
CO2024013744A2 (es) Moduladores de nlrp3
CO2023004346A2 (es) Formulaciones de un modulador de somatostatina
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
CO2022014499A2 (es) Moduladores de nlrp3
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
CO2024000880A2 (es) Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con at2r y/o señalización mediada por at2r
BR112018013247A2 (pt) tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
MX2022013864A (es) Moduladores del receptor cannabinoide tipo 2 (cb2) y usos de los mismos.
CL2024001109A1 (es) Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos.
ECSP22048726A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
CR20250341A (es) Moléculas de ácido nucleico
GT200600274A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado y su uso como agentes farmacétuicos